SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Blueprint Medicines Corporation (BPMC) , forward earnings yield 0.71%. PEG 1.31.
Criteria proven by this page:
- VALUE (60/100, Pass) — composite valuation score exceeds the 60/100 pass threshold.
- Forward P/E 141.0
- PEG Ratio 1.31 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Analyst consensus target $141.00 (+8.9% upside) — modest upside expected.
Overall SharesGrow Score: 46/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BPMC
Valuation Multiples
P/E (TTM)0.0
Forward P/E141.0
PEG Ratio1.31
Forward PEG1.31
P/B Ratio0.00
P/S Ratio15.99
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.07
Forward EPS (Est.)$0.92
Book Value / Share$0.00
Revenue / Share$8.09
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.71%
Dividend Yield0.00%
Analyst Target$141.00 (+8.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-2.89 |
$11.4M |
$-52.77M |
-462.9% |
| 2016 |
$-2.64 |
$27.77M |
$-72.5M |
-261% |
| 2017 |
$-3.92 |
$21.43M |
$-148.12M |
-691.3% |
| 2018 |
$-5.39 |
$44.52M |
$-236.64M |
-531.5% |
| 2019 |
$-6.87 |
$66.51M |
$-328.7M |
-494.2% |
| 2020 |
$5.59 |
$793.74M |
$313.88M |
39.5% |
| 2021 |
$-11.01 |
$180.08M |
$-644.09M |
-357.7% |
| 2022 |
$-9.35 |
$204.04M |
$-557.52M |
-273.2% |
| 2023 |
$-8.37 |
$249.38M |
$-506.98M |
-203.3% |
| 2024 |
$-1.07 |
$508.82M |
$-67.09M |
-13.2% |
